Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 3, 1998, Pages 501-510

  Hanks, Gerald E ^a   Hanlon, Alexandra L ^a   Schultheiss, Timothy E ^a   Pinover, Wayne H ^a   Movsas, Benjamin ^a   Epstein, Barry E ^a   Hunt, Margie A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

3D conformal technique; Dose response; Prostate cancer; Radiation treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; RADIATION RESPONSE; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR VOLUME; UROGENITAL TRACT DISEASE;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED;

EID: 0031781805     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00089-3     Document Type: Article

References (36)

1. Perez C.A., Hanks G.E., Leibel S.A., Zietman A.L., Fuks Z., Lee W.R. Localized carcinoma of the prostate (Stages T1B, T1C, T2, and T3). Int. J. Radiat. Oncol. Biol. Phys. 72:1993;3156-3173.
2. Hanks G.E. Optimizing the radiation treatment and outcome of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 11:1985;1235-1245.
3. Fuks Z., Leibel S.A., Wallner K.E., Begg C.B., Fair W.R., Anderson L.L., Basil S., Hilaris B.S., Whitmore W.W.F. The effect of local control on metastatic dissemination in carcinoma of the prostate Long term results in patients treated with I-125 implantation . Int. J. Radiat. Oncol. Biol. Phys. 21:1991;537-547.
4. Hanks G.E., Lee W.R., Hanlon A.L., Hunt M., Kaplan E., Epstein B.E., Schultheiss T.E. Conformal technique dose escalation for prostate cancer Improved cancer control with higher doses in patients with pretreatment PSA ≥10 ngm/ml . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;861-868.
5. Hanks G.E., Schultheiss T.E., Hanlon A.L., Hunt M., Lee W.R., Epstein B.E., Coia L.R. Optimization of conformal radiation treatment of prostate cancer Report of a dose escalation study . Int. J. Radiat. Oncol. Biol. Phys. 37:1997;543-550.
6. Leibel S.A. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate Interim report of a phase 1 dose-escalation study . Int. J. Radiat. Oncol. Biol. Phys. 152:1994;1792-1798.
7. Sandler H.M., Perez-Tamayo C., Ten Haken R.K., Lichter A.S. Dose escalation for stage C (T3) prostate cancer Minimal rectal toxicity observed using conformal therapy . Radiother. Oncol. 23:1992;53-54.
8. Pollack A., Zagars G.K., Starkschall G., Childress C., Kopplin S., Boyer A.L., Rosen I.I. Conventional vs. conformal radiotherapy for prostate cancer Preliminary results of dosimetry and acute toxicity . Int. J. Radiat. Oncol. Biol. Phys. 34:1996;555-564.
9. Shipley W.U., Verhey L.J., Munzenrider J.E., Suit H.D., Phil D., Urie M.M., McManus P.L., Young R.H., Shipley J.W., Zietman A.L., Biggs P.J., Heney N.M., Goitein M. Advanced prostate cancer The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone . Int. J. Radiat. Oncol. Biol. Phys. 32:1995;3-12.
10. Forman J.D., Duclos M., Sharma R., Chuba P., Hart K., Yudelev M., Devi S., Court W., Shamsa F., Littrup P., Grignon D., Porter A., Maughan R. Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer Preliminary estimates of the therapeutic ratio . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;259-266.
11. Forman J.D., Dulcos M., Shamsa F., Porter A.T., Orton C. Hyperfractionated conformal radiotherapy in locally advanced prostate cancer Results of a dose escalation study . Int. J. Radiat. Oncol. Biol. Phys. 34:1996;655-662.
12. Hanlon A.L., Schultheiss T.E., Hunt M.A., Movsas B., Peter R.S., Hanks G.E. Chronic rectal bleeding after high dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;59-63.
13. Teshima T., Hanks G.E., Hanlon A.L., Peter R.S., Schultheiss T.E. Rectal bleeding after conformal 3D treatment of prostate cancer Time to occurrence, response to treatment and duration of morbidity . Int. J. Radiat. Oncol. Biol. Phys. 39:1997;77-83.
14. Hanks, G. E.; Schultheiss, T. E.; Hunt, M. Clinical experience with 3D radiotherapy treating prostate cancer. Proceedings of International Symposium on 3D Radiation Treatment of Prostate Cancer, St. Louis, MO. 1993.
15. Hanks G.E., Hanlon A.L., Schultheiss T.E., Freedman G., Hunt M., Pinover W., Movsas B. Conformal external beam treatment of prostate cancer. Urol. 50:1997;87-92.
16. ICRU Report No. 50. International Commission on Radiation Units and Measurements: Prescribing, Recording, and Reporting Photon Beam Therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993.
17. Hanlon, A. L.; Fowble, B. L.; Hanks, G. E. Accounting for competing risks is essential in comparing surgery and radiation treatment of prostate cancer. ASTRO Abstract, 1997 (submitted).
18. Kalbfleisch J.D., Ross L.P. The statistical analysis of failure time data. 1980;John Wiley, New York.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;447-457.
20. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annual Statistics. 16:1988;1141-1143.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;163-170.
22. Cox D.R. Regression models and life tables. J. Royal Stat. Soc. 34:1972;187-220.
23. I. SAS/STAT users guide, version 6. 1989;846 SAS Institute, Inc, Cary, NC.
24. Sheskin D. Handbook of parametric and nonparametric statistical procedures. 1997;CRC Press, Boca Raton, FL.
25. Anderson, P.; Hanlon, A.; Patchefsky, A.; Al-Saleem, T.; Hanks, G. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml. Int. J. Radiat. Oncol. Biol. Phys. In press.
26. Lee W.R., Hanks G.E., Hanlon A., Schultheiss T.E., Hunt M.A. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer Further evidence for a significant dose effect . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;251-257.
27. Sandler H.M. 3-D conformal radiotherapy for prostate cancer The University of Michigan Experience . 1996;238-243 S. Karger, Basel.
28. Sandler H.M., McLaughlin P.W., TenHaken R.K., Addison H., Forman J., Lichter A. Three dimensional conformal radiotherapy for the treatment of prostate cancer Low risk of chronic rectal morbidity observed in a large series of patients . Int. J. Radiat. Oncol. Biol. Phys. 33:1995;797-801.
29. Fukanaga-Johnson N., Sandler H.M., McLaughlin W., Strawderman M.S., Grijalva K.H., Kish K.E., Lichter A.L. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;311-318.
30. Leibel S.A., Heimann R., Kutcher G.J., Zelefsky M.J., Burman C.B., Melain E., Orazem J.P., Mohan R., LoSasso T.J., Lo Y.C., Wiseberg J., Chapman D.S., Ling C.C., Fuks Z. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate Preliminary results of a Phase I dose-escalation study . Int. J. Radiat. Oncol. Biol. Phys. 28:1993;55-65.
31. Zelefsky M.J., Leibel S.A., Kutcher G.J., Kelson S., Ling C., Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J. Sci. Am. 1:1995;142-150.
32. Hanks G.E. A question-filled future for dose-escalation in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;891.
33. Lattanzi J.P., Hanlon A.L., Hanks G.E. Early stage prostate cancer treated with radiation therapy Stratifying an intermediate risk group . Int. J. Radiat. Oncol. Biol. Phys. 38:1997;569-573.
34. Lattanzi, J.; McNeely, S.; Barnes, S.; Das, I.; Schultheiss, T. E.; Hanks, G. E. Initial results of using daily CT localization to correct portal error in prostate cancer. ASTRO Abstract, 1997 (submitted).
35. Pilepich M.V., Caplan R., Byhardt R.W., Lawton C.A., Gallagher M.J., Mesic J.B., Hanks G.E., Coughlin C.T., Porter A. Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy - Report of RTOG 85-31. J. Clin. Oncol. 15:1997;1013-1021.
36. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., Bernier J., Kuten A., Sternberg C., Gil T., Collette L., Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337:1997;295-300.